SCHEMBL716631

SCHEMBL716631

CCOC(=O)c1c[nH]nc1CCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.50
RAB9A P51151 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
MAPT P10636 3/20 0.47
NPC1 O15118 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
PDE3B Q13370 1/20 0.45
PDE3A Q14432 1/20 0.45
ALDH1A1 P00352 1/20 0.44
HSD17B10 Q99714 1/20 0.44
P2RX3 P56373 1/20 0.44
GABRA1 P14867 1/20 0.44
GABRB1 P18505 1/20 0.44
GABRA3 P34903 1/20 0.44
GABRB2 P47870 1/20 0.44
ALOX5 P09917 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4014406 0.92 TSHR (0.47) TSHRRAB9ANPSR1SMN1; SMN2MAPT
SCHEMBL5778710 0.87 SMN1; SMN2 (0.52) TSHRRAB9ANPSR1SMN1; SMN2MAPT
SCHEMBL6228468 0.87 TSHR (0.45) TSHRRAB9ANPSR1SMN1; SMN2MAPT
SCHEMBL7512109 0.84 TSHR (0.47) TSHRRAB9ANPSR1SMN1; SMN2MAPT
SCHEMBL22534331 0.82 KDM5B (0.46) RAB9ASMN1; SMN2NPC1ALDH1A1P2RX3
SCHEMBL2820788 0.82 HSP90AA1 (0.52) TSHRMAPTALDH1A1HSD17B10L3MBTL1
SCHEMBL28996611 0.80 ALDH1A1 (0.45) TSHRMAPTCYP1A2ALDH1A1HSD17B10
SCHEMBL9034386 0.79 PDE3B (0.45) TSHRRAB9ANPSR1SMN1; SMN2MAPT
SCHEMBL3356162 0.79 KMT2A (0.49) TSHRMAPTALDH1A1HSD17B10GABRA1
SCHEMBL30793043 0.78 KMT2A (0.43) TSHRRAB9ASMN1; SMN2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP TSHR 1555/4885RAB9A 2454/4885NPSR1 2548/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP TSHR 1555/4885RAB9A 2454/4885NPSR1 2548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.